|
|
|
| Effect of Recombinant Humanized Anti IL-6R Monoclonal Antibody on Clinical Efficacy and Bone Metabolism in Rheumatoid Arthritis |
| GE Hongliang, XIE Jie, LIU Yuwen, HU Jiankang |
| First-author's address: Pingxiang People's Hospital, Jiangxi Province, Pingxiang 337000, China |
|
|
|
|
Abstract Objective: To investigate the effect of Recombinant Humanized Anti IL-6R Monoclonal Antibody on the clinical efficacy and bone metabolism in rheumatoid arthritis (RA). Method: A total of 60 patients diagnosed with RA in Pingxiang People's Hospital from August 2019 to March 2022 were selected and divided into treatment group and control group according to random number table method, with 30 patients in each group. The treatment group was treated with Recombinant Humanized Anti IL-6R Monoclonal Antibody + Methotrexate + stable dose Prednisone, while the control group was treated with Methotrexate + stable dose Prednisone. The C reactive protein, rheumatoid factor, erythrocyte sediment, osteocalcin (OC) and bone mineral density of the two groups were detected before treatment and 3 and 6 months after treatment, visual analogue scale (VAS) score, Sharp score and safety of the two groups were evaluated. Result: After 3 and 6 months of treatment, the C reactive protein, rheumatoid factor, erythrocyte sedimentation rate and VAS scores in two groups were significantly lower than those before treatment (P<0.05), and the above indexes in the treatment group were significantly lower than those in the control group (P<0.05). The OC of 3 and 6 months after treatment in both groups were higher than those before treatment (P<0.05), and the OC of 3 and 6 months after treatment in the treatment group were higher than those of control group (P<0.05). There were no significant differences in femoral neck bone mineral density before and after treatment between the two groups and within two groups (P>0.05). Sharp scores of 3 and 6 months after treatment in the two groups were lower than those before treatment (P<0.05), and Sharp scores of 3 and 6 months after treatment in the treatment group were lower than those in the control group (P<0.05). The incidence of adverse events in the treatment group was higher than that in the control group, but there was no significant difference between the two groups (P>0.05). Conclusion: Recombinant Humanized Anti IL-6R Monoclonal Antibody can effectively reduce the levels of C reactive protein, rheumatoid factor and erythrocyte sink in RA patients, relieve their pain, increase OC, reduce Sharp score, and do not increase the occurrence of adverse events, with high safety.
|
|
Received: 19 January 2023
|
|
|
|
|
|
|
